GlassScriptPhysician profile
Kyleigh Benton
NPI 1902336191
$3,464.84
in general payments reported to CMS, 2019-2025
38 companies · $720 in 2025
The $720 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,518 · 2022: $280 · 2023: $343 · 2024: $604 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,666.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $597.19 | 2021-2025 | |
| Corium, LLC | $359.43 | 2022-2025 | Azstarys |
| Lilly USA, LLC | $323.07 | 2021-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $247.56 | 2021-2025 | Airsupra, Breztri |
| Astellas Pharma US INC | $186.39 | 2021-2025 | Veozah |
| Pfizer INC. | $153.29 | 2021-2025 | |
| Antares Pharma, INC. | $142.24 | 2021-2025 | Xyosted |
| Takeda Pharmaceuticals U.S.A., INC. | $134.04 | 2021 | |
| Abbott Laboratories | $128.34 | 2021-2024 | Jot Dx, Assurity |
| Novo Nordisk INC | $120.10 | 2021-2025 | Wegovy |
| Amgen INC. | $120.08 | 2021-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.04 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $80.02 | 2021-2025 | Shingrix |
| Eisai INC. | $69.50 | 2021 | |
| Merck Sharp & Dohme LLC | $54.85 | 2021 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyleigh Benton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.